Clinical-stage biotechnology company Latigo Biotherapeutics Inc. (Latigo) announced on Monday that it has named Tim Lugo as its new chief financial officer (CFO).
Lugo has two decades of experience as a financial analyst covering the biotechnology and pharmaceutical sectors. He has served as a partner and group head of biotechnology equity research at William Blair. He has also worked at Pacific Growth Equities as a junior analyst. He serves on the board of trustees at Children's Day School in San Francisco.
Lugo has a BA in molecular and cellular biology and a BA in economics, both from the University of California, Berkeley.
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business
Insmed receives highest ranking in Science's 2024 Top Employers Survey
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
Viatris added to Forbes' World's Best Employers 2024 list
Rarity Health named finalist for 21st MM+M Rare Disease Agency of the Year